Multiple Sclerosis International / 2013 / Article / Tab 1

Clinical Study

Assessment of Definitions of Sustained Disease Progression in Relapsing-Remitting Multiple Sclerosis

Table 1

Baseline demographic and clinical characteristics in study sample.

929
Gender (% female)75
Age (years, mean ± SD)
Disease duration (years, mean ± SD)
Race (% white)95
Follow-up time (months, mean ± SD)
EDSS (mean ± SD)
Pyramidal scale (mean ± SD)
Cerebellar scale (mean ± SD)
Brainstem scale (mean ± SD)
Sensory scale (mean ± SD)
Bowel bladder scale (mean ± SD)
Mental scale (mean ± SD)
Visual scale (mean ± SD)
Treatment (% IFN, % GA, % other, % untreated)29.7, 30.9, 7.2, 32.2

EDSS: expanded disability status scale, IFN: all forms of interferon- , GA: glatiramer acetate, other: natalizumab, rituximab, cyclophosphamide, daclizumab, mycophenolate mofetil, mitoxantrone, or combination treatment.